NovaBridge Biosciences (NBP) Non-Current Deffered Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Non-Current Deffered Revenue for 6 consecutive years, with $40.6 million the latest figure, recorded in Q4 2023.

• Quarterly Non-Current Deffered Revenue rose 7.72% year-over-year to $40.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $40.6 million (up 7.72% YoY) and the FY2023 annual result came in at $41.2 million, up 1618.54% from the prior year.
• Non-Current Deffered Revenue advanced to $40.6 million in Q4 2023 per NBP's latest filing, from $36.9 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for NBP reached as high as $35.0 billion in Q4 2021 and fell as low as $556172.6 in Q4 2019.
• A 5-year average of $5.0 billion and a median of $36.9 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue soared 53.82% — and 2022, when it sank 99.89%.
• Year by year, Non-Current Deffered Revenue stood at $556172.6 in 2019, then rose by 20.83% to $672000.0 in 2020, then surged by 5213553.04% to $35.0 billion in 2021, then plunged by 99.89% to $37.7 million in 2022, then climbed by 7.72% to $40.6 million in 2023.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $40.6 million, $36.9 million, and $37.7 million for Q4 2023, Q2 2023, and Q4 2022 respectively.